Here, the authors demonstrate that inactivating driver mutations in TGFBR1 and TGFBR2 occur in vemurafenib-induced and sporadic cutaneous squamous cell carcinomas. This evidence concerns the gene TGFBR1 and cutaneous squamous cell carcinoma.